Form 4: Inmune Bio Director Scott Juda Acquires Shares and Warrants in Direct Offering

Director Scott Juda purchased 29,603 shares of Inmune Bio stock and warrants in a registered direct offering.

Summary

• On April 19, 2024, Scott Juda, a director of Inmune Bio, Inc., acquired 29,603 shares of common stock at $8.32 per share.
• The purchase was part of a registered direct offering.
• Juda also acquired warrants to purchase 29,603 shares of common stock at an exercise price of $9.152 per share.
• The aggregate purchase price for the shares and warrants was $249,997.34.
• Following the transaction, Juda directly owns 66,603 shares of Inmune Bio stock.
• The warrants are exercisable immediately and expire two years from the initial exercise date or thirty trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, with a potential extension for directors, officers, or affiliates subject to a blackout period.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director's purchase of shares suggests confidence, but the warrants introduce some complexity and dependence on future performance.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Risks

• The warrants' expiration is tied to the reporting of top-line data from the Phase 2 Alzheimer's program, which introduces uncertainty related to the trial's timeline and outcome.
• The value of the warrants is dependent on the stock price exceeding the exercise price of $9.152.

Future Outlook

The warrants' value is contingent on the company's performance and the stock price exceeding the exercise price before the expiration date, which is linked to the Phase 2 Alzheimer's program data release.

Industry Context

Direct offerings are a common way for biotech companies to raise capital. Director participation can signal confidence in the company's prospects, but the specific terms of the offering (e.g., warrant coverage) can influence investor perception.

Comparison to Industry Standards

• Comparing the warrant terms (exercise price, expiration) to similar biotech financings would provide context on whether the terms are favorable or unfavorable to the investor.
• Analyzing the size of the director's investment relative to their existing holdings and the company's market capitalization can provide insights into the significance of the transaction.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• The capital raised through the direct offering can support the company's research and development efforts.

Next Steps

• Monitor the company's progress on the Phase 2 Alzheimer's program and the timing of the data release.
• Track the stock price relative to the warrant exercise price to assess the potential value of the warrants.

Key Dates